Spectral Flow Cytometry: From Trade-Offs to Total Clarity

The Challenge with Traditional Flow Cytometry 

When developing cell and gene therapies, understanding the complete immune landscape isn’t optional – it’s critical. 

Yet traditional optical filter-based flow cytometry forces an impossible trade-off:

  • Analyze more parameters or maintain resolution.

This compromise leads to:

  • Missed low-expressed antigens
  • Spillover artifacts from compensation
  • Limited immunophenotyping
  • Decisions based on partial data

Your therapy deserves better.

Resolian Bioanalytics Flow Cytometry

Cytek Aurora + Resolian Expertise
= Complete Immune Clarity

At Resolian, we’ve eliminated the trade-off. By combining the Cytek Aurora Full Spectrum Profiling platform with over 25 years of flow cytometry mastery, we unlock what traditional systems miss.

What This Unlocks

  • Highly multicolor panels in a single run – myriad combinations
  • Simultaneous monitoring of blood and bone marrow populations
  • Rare cell subsets alongside major immune compartments
  • High-dimensional data precision without compromise

Advanced Technology Needs Advanced Expertise

The Cytek Aurora’s power requires more than hardware. It demands:

  • Complex panel design for highly multicolor analysis
  • Spectral unmixing mastery to eliminate artifacts
  • Rare population detection with creative solutions
  • Data interpretation that turns complexity into actionable insights
  • Regulatory alignment for global compliance

Technology + Expertise = Confident Decisions.

Complementary capabilities – biomarkers, immunogenicity, and PCR – integrate seamlessly with your cytometry endpoints for a holistic view across PK/PD and efficacy.

Cytek Aurora + Resolian Expertise = Complete Immune Clarity

Why Resolian?

When precision matters, experience delivers. Resolian transforms:

  • Complex spectral data → Clear insights
  • Advanced technology → Strategic advantage
  • Immune monitoring → Confident therapy development

Ready to See the Complete Picture?


Start your journey with Resolian.
Talk to our team about custom spectral flow cytometry solutions designed for your cell & gene therapy program.

Scroll to Top

Zhiyang Zhao, Ph.D.

Chief Scientific Officer

Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade. 

Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia. 

 

Patrick Bennett

Chief Executive Officer

Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD. 

Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.